These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20649394)

  • 1. Addressing the health technology assessment of biosimilar pharmaceuticals.
    Stewart A; Aubrey P; Belsey J
    Curr Med Res Opin; 2010 Sep; 26(9):2119-26. PubMed ID: 20649394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?
    ; Neumann PJ; Drummond MF; Jönsson B; Luce BR; Schwartz JS; Siebert U; Sullivan SD
    Int J Technol Assess Health Care; 2010 Jan; 26(1):71-8. PubMed ID: 20059783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Historical development of health technology assessment in Thailand.
    Teerawattananon Y; Tantivess S; Yothasamut J; Kingkaew P; Chaisiri K
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():241-52. PubMed ID: 19527543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin biosimilars in Europe: five years on.
    Mikhail A; Farouk M
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basic facts about biosimilars.
    Nowicki M
    Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key principles for the improved conduct of health technology assessments for resource allocation decisions.
    Drummond MF; Schwartz JS; Jönsson B; Luce BR; Neumann PJ; Siebert U; Sullivan SD
    Int J Technol Assess Health Care; 2008; 24(3):244-58; discussion 362-8. PubMed ID: 18601792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. History of health technology assessment in Belgium.
    Cleemput I; Van Wilder P
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():82-7. PubMed ID: 19500438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis and policy choices: investing in health systems.
    Murray CJ; Kreuser J; Whang W
    Bull World Health Organ; 1994; 72(4):663-74. PubMed ID: 7923545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and implementation of health technology assessment in Argentina: two steps forward and one step back.
    Rubinstein A; Pichon-Riviere A; Augustovski F
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():260-9. PubMed ID: 19527545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory aspects of biosimilars in Europe.
    Zuñiga L; Calvo B
    Trends Biotechnol; 2009 Jul; 27(7):385-7. PubMed ID: 19467723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health technology assessment.
    Papatheofanis FJ
    Q J Nucl Med; 2000 Jun; 44(2):105-11. PubMed ID: 10967621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health technology assessment in South Korea.
    Kim CY
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():219-23. PubMed ID: 19527540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
    Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
    Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluations conducted by Canadian health technology assessment agencies: where do we stand?
    Tarride JE; McCarron CE; Lim M; Bowen JM; Blackhouse G; Hopkins R; O'Reilly D; Xie F; Goeree R
    Int J Technol Assess Health Care; 2008; 24(4):437-44. PubMed ID: 18828938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of health technology assessment in the comprehensive evaluation of the impact of immunotherapy on real practice.
    Frati F; Ariano R; Cadario G; Ortolani C; Passalacqua G
    Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():4-6. PubMed ID: 18924459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA.
    Kristensen FB; Lampe K; Chase DL; Lee-Robin SH; Wild C; Moharra M; Garrido MV; Nielsen CP; Røttingen JA; Neikter SA; Bistrup ML;
    Int J Technol Assess Health Care; 2009 Dec; 25 Suppl 2():1-8. PubMed ID: 20030885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological agents and biosimilars: Essential information for the internist.
    Pasina L; Casadei G; Nobili A
    Eur J Intern Med; 2016 Sep; 33():28-35. PubMed ID: 27342030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.